《阿托伐他汀能够改善激素耐药型免疫性血小板减少患者的骨髓血管内皮细胞功能》解读

孔圆; 黄晓军

doi:10.13201/j.issn.1004-2806.2020.01.001

《阿托伐他汀能够改善激素耐药型免疫性血小板减少患者的骨髓血管内皮细胞功能》解读

孔圆,
黄晓军

- 北京大学人民医院、北京大学血液病研究所、国家血液系统疾病临床医学研究中心、造血干细胞移植治疗血液病北京市重点实验室(北京, 100044)
基金项目:
国家自然科学基金项目(No:81530046、81870139)

详细信息

通讯作者: 黄晓军,博士生导师,教授,北京大学人民医院血液病研究所所长,国家血液系统疾病临床医学研究中心负责人,国家基金委创新群体、科技部、教育部创新团队带头人,国家重点学科、国家临床重点专科负责人。兼任亚太血液联盟常委会主任、第九届中国病理生理学会实验血液学专业委员会主任委员、第四届中国医师协会血液科医师分会会长、中国医疗保健国际交流促进会血液学分会主任委员,第九届中华医学会血液学分会主任委员、美国血液学会国际常委会委员、国际白血病比较研究组织全球委员会委员。主持“国家重点研发计划”、“863”项目、国自然“杰青”、重点项目等国家级课题。近年来,以通讯或第一作者发表SCI论文300余篇,包括New Engl J Med、Lancet Oncol、J Clin Oncol、Blood和Leukemia等,入选2014-2018年中国高被引学者榜单(医学)。牵头制定17项指南/共识,带领团队取得的研究成果已被美国、英国骨髓移植协会、美国国家癌症研究所等40余项国际指南或共识引用。排名第一获国家科技进步二等奖2项、省部级一等奖4项,荣获何梁何利科学技术与进步奖、吴阶平医药创新奖、转化医学杰出贡献奖和谈家桢生命科学奖。担任《中华血液学杂志》总编辑、British Journal of Haematology副主编,Journal of Hematology and Oncology副主编,Chin Med J(Engl)副主编,Annals of Hematology高级编委

中图分类号: R558.2

收稿日期: 2019-11-14

Comments on "Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients"

More Information

Corresponding author: HUANG Xiaojun

Received Date: 14 November 2019

摘要

摘要: 本文最初作为封面焦点文章发表于2018年Blood杂志上,Blood杂志当期配发专家述评。文章题录为:Kong Y,Cao XN,Zhang XH,et al.Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients[J].Blood,2018,131:1219-1233.文章采用前瞻性配对临床队列研究,首次从骨髓血管内皮细胞角度揭示了激素耐药型免疫性血小板减少的全新发病机制及其临床干预策略,有望为建立激素耐药型免疫性血小板减少患者的新型防治体系奠定理论基础。经通信作者许可,再次通过佳文解读的方式来阐述这一发现。
- 激素耐药型免疫性血小板减少 /
- 骨髓血管内皮细胞 /
- 阿托伐他汀 /
- 活性氧 /
- 乙酰半胱氨酸
- corticosteroid-resistant immune thrombocytopenia /
- bone marrow endothelial cells /
- atorvastatin /
- re-active oxygen species /
- N-acetyl-L-cysteine

HTML全文

参考文献(23)

[1]	Rodeghiero F,Stasi R,Gernsheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood,2009,113:2386-2393.
[2]	Cines DB,Bussel JB,Liebman HA,et al.The ITP syndrome:pathogenic and clinical diversity[J].Blood,2009,113:6511-6521.
[3]	Zhu X,Zhang J,Wang Q,et al.Diminished expression of beta2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia[J].Ann Hematol,2018,97:641-654.
[4]	Cuker A,Neunert CE.How I treat refractory immune thrombocytopenia[J].Blood,2016,128:1547-1554.
[5]	Feng FE,Feng R,Wang M,et al.Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia:a multicentre,randomised,open-label,phase 2 trial[J].Lancet Haematol,2017,4:e487-e496.
[6]	Wang L,Xu L,Hao H,et al.First line treatment of adult patients with primary immune thrombocytopenia:a real-world study[J].Platelets,2019 Feb 11:1-7.doi:10.1080/09537104.2019.1572875.[Epub ahead of print].
[7]	中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(2):89-93.
[8]	Zhou H,Qin P,Liu Q,et al.A prospective,multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia[J].Am J Hematol,2019 Oct 7.doi:10.1002/ajh.25646.[Epub ahead of print].
[9]	De Botton S,Sabri S,Daugas E,et al.Platelet formation is the consequence of caspase activation within megakaryocytes[J].Blood,2002,100:1310-1317.
[10]	Morrison SJ,Scadden DT.The bone marrow niche for haematopoietic stem cells[J].Nature,2014,505:327-334.
[11]	Rafii S,Shapiro F,Pettengell R,et al.Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors[J].Blood,1995,86:3353-3363.
[12]	Psaila B,Lyden D,Roberts I.Megakaryocytes,malignancy and bone marrow vascular niches[J].J Thromb Haemost,2012,10:177-188.
[13]	Vaughan CJ,Murphy MB,Buckley BM.Statins do more than just lower cholesterol[J].Lancet,1996,348:1079-1082.
[14]	Oikonomou E,Siasos G,Zaromitidou M,et al.Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients[J].Atherosclerosis,2015,238:159-164.
[15]	Kong Y.Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights☆[J].Semin Hematol,2019,56:215-220.
[16]	Kong Y,Chang YJ,Wang YZ,et al.Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant,2013,19:1465-1473.
[17]	Kong Y,Shi MM,Zhang YY,et al.N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation[J].Am J Hematol,2018,93:931-942.
[18]	Kong Y,Song Y,Hu Y,et al.Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants[J].Oncotarget,2016,7:30892-30906.
[19]	Kong Y,Song Y,Tang FF,et al.N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant[J].Br J Haematol,2018,180:863-878.
[20]	Kong Y,Wang Y,Zhang YY,et al.Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation[J].Blood Adv,2019,3:1303-1317.
[21]	Kong Y,Wang YT,Hu Y,et al.The bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft function[J].Bone Marrow Transplant,2016,51:249-255.
[22]	Shi MM,Kong Y,Song Y,et al.Atorvastatin enhances endothelial cell function in posttransplant poor graft function[J].Blood,2016,128:2988-2999.
[23]	Zhao HY,Lyu ZS,Duan CW,et al.An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation[J].Br J Haematol,2018,182:679-692.